TP53 and acute myeloid leukemia: In one of these reports involving newly diagnosed AML, [14] unlike the case in the current study, responses to HMA + venetoclax were documented in 8 (32%) of 25 TP53-mutated AML cases, most of whom expressed monoallelic TP53 alteration.